S100A4 and cancer: Since targeting CAFs has been recognized as a potential therapeutic strategy of cancer treatment [45], our research suggested that concurrently administering CLDN18.2-targeted therapies along with S100A4 inhibitors (or other CAF-targeted regimens) may disrupt this interplay and significantly enhance the therapeutic outcome.